
Opinion|Videos|August 1, 2024
Unmet Needs in IPF Landscape
Author(s)Justin Oldham, MD, MS
Critical voids in the management of idiopathic pulmonary fibrosis are discussed by Justin Oldham, MD, MS.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- What are the current unmet needs in IPF treatment and why is it necessary to develop new pharmacotherapies for this disease?
- What biomarkers are currently used for the diagnosis of IPF?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Nerandomilast for Idiopathic Pulmonary Fibrosis
2
Pulling Back Funding for Research COuld Leave HIV Treatment in Worse State: Patrick Sullivan, DVM, PhD
3
Value-Based Care Interventions and Management of CKD Progression
4
HMA Combination Therapy Boosts Survival in Accelerated- or Blast-Phase MPNs
5